EP
IOVA icon

Edgestream Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Edgestream Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-99,605
Closed -$799K – 958
2024
Q2 		$799K Buy
+99,605
New +$1.07M 0.04% 575
2023
Q4 		– Sell
-65,184
Closed -$297K – 943
2023
Q3 		$297K Buy
+65,184
New +$426K 0.02% 715

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Edgestream Partners's IOVA Position: Q3 2024 in Review

Edgestream Partners sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 99,605 shares — an estimated $799K sold.

Edgestream Partners first reported a position in IOVA in Q3 2023 and held it in 2 quarters. The position peaked at $799K in Q2 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Edgestream Partners reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Edgestream Partners sold 99,605 Iovance Biotherapeutics shares in Q3 2024, an estimated $799K.
  • Edgestream Partners first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 2 quarters.
  • Edgestream Partners's Iovance Biotherapeutics position peaked at $799K in Q2 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Edgestream Partners's 13F filing for Q3 2024, filed 14 Nov 2024.